According to recent reports by NPR, a promising drug to treat Respiratory Syncytial Virus (RSV), a virus that is especially dangerous for small children, could soon be available for toddlers.
The reported drug is an inhalable powder that was approved by the Food and Drug Administration (FDA) in February of 2018. It is a single-dose powder that can be inhaled at home, and it has already been shown to be effective in reducing the spread of the virus in young infants.
The drug, known as Synagis, is made of antibodies that help fight off RSV and is the only FDA-approved drug that can be used in children. Because the virus is so contagious, it is especially important that the drug be available to toddlers and young children who are most vulnerable to its spread.
What makes this drug unique is that it is the first to be approved for children this young, as well as the first to be taken at home, giving parents a much-needed solution for keeping their children safe from this virus.
The drug will cost about $3,500 for a full year’s supply, and is likely to be available sometime in the next few months. This news is particularly exciting for parents and medical professionals, as it will be one of the few treatments available for the prevention of RSV.
The potential of this drug is very promising, and it could potentially be invaluable in stopping the spread of RSV among young children. With the current level of virus activity, the availability of this drug could greatly reduce the risk of children suffering from RSV and its complications.
If this drug proves to be effective as originally hoped, this could mark a major milestone in the fight against RSV. [ad_1]
A new drug to protect against extreme RSV infections could shortly be readily available for youthful infants. Up to 80,000 young children get hospitalized with RSV every single calendar year in the U.S.
Copyright © 2023 NPR. All rights reserved. Visit our web page phrases of use and permissions web pages at www.npr.org for more information and facts.
NPR transcripts are created on a hurry deadline by an NPR contractor. This text may possibly not be in its final form and could be up-to-date or revised in the potential. Accuracy and availability may perhaps vary. The authoritative record of NPR’s programming is the audio report.